玻璃膜疣:地图状萎缩与黄斑新生血管的风险
该研究对63眼(38例,平均58.9岁)玻璃膜疣患者进行随访,平均40个月,发现地图状萎缩(GA)5年累积风险为28.4%,黄斑新生血管(MNV)为8.7%;表型2和3进展风险显著高于表型1(P=0.0015)。
要点
- 玻璃膜疣患者GA的5年累积风险为28.4%,MNV为8.7%。
- 表型2和3的5年MNV或GA发生率分别为50.0%和51.6%,显著高于表型1的12.6%(P=0.0015)。
- 玻璃膜疣常在50岁左右诊断,女性多见,应使用多模态影像监测进展。
核心结论
- 玻璃膜疣患者纵向随访中,表型2和表型3进展为GA或MNV的风险显著。
- 玻璃膜疣可能属于年龄相关性黄斑变性的整体疾病谱。
研究设计与样本
- 连续病例系列,纳入38例患者共63眼,平均随访40±18个月。
- 根据眼底表现将玻璃膜疣分为三种表型:表型1为黄斑及旁黄斑密集分布,表型2为后极部散在分布,表型3为玻璃膜疣混合大于200微米的大玻璃膜疣。
- 采用Kaplan-Meier法估计5年进展风险。
主要发现
- GA发生于19.0%(12/63)的眼,MNV发生于4.8%(3/63)的眼。
- GA和MNV的5年累积风险分别为28.4%和8.7%。
- 表型1、2、3的5年MNV或GA发生率分别为12.6%、50.0%、51.6%(P=0.0015,log-rank检验)。
- 单眼已患GA或MNV的患者与双眼均纳入的患者在进展风险上无差异(P=0.11)。
关键数值与推荐
- 玻璃膜疣表型1:黄斑及旁黄斑区密集分布的玻璃膜疣。
- 玻璃膜疣表型2:后极部散在分布的玻璃膜疣。
- 玻璃膜疣表型3:玻璃膜疣混合大于200微米的大玻璃膜疣。
临床怎么用
- 对玻璃膜疣患者应使用多模态影像检测,并警惕进展为GA或MNV的风险。
- 根据表型分层评估进展风险,表型2和表型3需更密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cuticular drusen (CD) have been associated with manifestations of age-related macular degeneration such as atrophy and neovascularization in the macula. In this study, eyes with CD were followed and investigated for the estimated 5-year risk of progression to sequelae of age-related macular degeneration such as geographic atrophy (GA) and macular neovascularization (MNV). METHODS: A consecutive series of patients with CD were followed for the development of GA and MNV. Whenever possible, they were also studied retrospectively. The patients with CD were categorized into three phenotypic groups. Phenotype 1: eyes had concentrated, densely populated CD in the macular and paramacular area, Phenotype 2: eyes showed scattered CD in the posterior fundus, and Phenotype 3: involved eyes with CD mixed with large drusen (>200 µm). The 5-year incidence of progression was then estimated using a Kaplan-Meier estimator. RESULTS: A total of 63 eyes from 38 patients (35 women with a mean age at presentation of 58.9 ± 14.2 years) were studied and followed for a mean of 40 ± 18 months. Thirteen patients had single eyes with GA (84.5%; 11/13) or MNV (15.5%; 2/13) in one eye at presentation and were subsequently excluded. Geographic atrophy developed in 19.0% (12/63) of eyes and MNV in 4.8% (3/63) of eyes. The cumulative estimated 5-year risk of GA and MNV was 28.4% and 8.7%, respectively. The estimated 5-year incidence of MNV or GA was 12.6%, 50.0%, and 51.6% in Phenotype 1, Phenotype 2, and Phenotype 3, respectively (P = 0.0015, log-rank test). No difference in risk was found in the development of GA or MNV (P = 0.11) between the subgroup of patients presenting with GA or MNV in their fellow eye and those with both eyes included. CONCLUSION: When patients with CD are followed longitudinally, there was a significant risk of progression to GA or MNV for Phenotype 2 and Phenotype 3. Patients with CD are commonly first diagnosed in the fifth decade of life, and there is a female predominance. Clinicians should use multimodal imaging to detect and be aware of the risk of progression to manifestations of GA and MNV. These risks of GA and MNV suggest that patients with CD may be part of the overall spectrum of age-related macular degeneration.
引用
- Sakurada Y, Parikh R, Gal-Or O, et al. CUTICULAR DRUSEN: Risk of Geographic Atrophy and Macular Neovascularization. Retina. 2020. PMID: 31972795. doi:10.1097/IAE.0000000000002399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。